Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer
Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer
复制标题
DOI：
10.1245/s10434-014-3984-z
复制
发表时间：
2015-01-01
影响因子：
3.7
通讯作者：
Bae, Young Kyung
中科院分区：
文献类型：
--
作者：
Choi, Jung Eun;Kang, Su Hwan;Bae, Young Kyung
一部分三阴性乳腺癌（triple-negative breast cancer，TNBC）表达雄激素受体（androgen receptor，AR），但AR表达的临床意义尚不清楚，我们检测了大量TNBC病例中AR的免疫组化表达，并将其表达与临床病理特征和临床结局相关联，发现AR表达在17.7%（87/492）的TNBC中。AR阳性表达与年龄（p < 0.001）、顶泌腺组织学类型（p = 0.001）和组织学分级（p < 0.001）有关。在单变量（p = 0.026）和多变量（p = 0.008）分析中，AR是总生存期（OS）的不良预后标志物。在淋巴结阴性（n = 316）亚组中，在单变量（p = 0.028和0.011）和多变量（分别为p = 0.024和0.01）分析中，AR表达是OS和无病生存期（DFS）较差的显著预测因子。AR表达也是pT 1亚组的预后因素（OS，p = 0.007; DFS，p = 0.01）;然而，在淋巴结转移或肿瘤大小大于pT 1的TNBC患者中未观察到其预后价值。AR表达TNBC代表具有不良临床结果的独特乳腺癌亚组，AR阻断可能是这些TNBC患者的潜在内分泌治疗。AR状态的评估可以提供TNBC患者预后和治疗的额外信息。
A subset of triple-negative breast cancer (TNBC) has been reported to express androgen receptor (AR); however, the clinical significance of AR expression in TNBC is unclear.We examined immunohistochemical expression of AR in a large cohort of TNBC cases and correlated its expression with clinicopathologic features and clinical outcome.AR expression was found in 17.7% (87/492) of TNBCs. Positive expression of AR showed significant correlation with older age (p < 0.001), apocrine histology (p = 0.001), and lower histologic grade (p < 0.001). AR was a poor prognostic marker for overall survival (OS) in univariate (p = 0.026) and multivariate (p = 0.008) analyses. In the lymph node-negative (n = 316) subgroup, AR expression was a significant predictor of worse OS and disease-free survival (DFS) in both univariate (p = 0.028 and 0.011) and multivariate (p = 0.024 and 0.01, respectively) analyses. AR expression also was a prognostic factor in pT1 subgroup (OS, p = 0.007; DFS, p = 0.01); however, its prognostic value was not observed in TNBC patients with lymph node metastasis or tumor size larger than pT1.AR-expressing TNBCs represent a distinct breast cancer subgroup with adverse clinical outcome and AR blockade could be a potential endocrine therapy for these TNBC patients. Evaluation of AR status may provide additional information on prognosis and treatment in patients with TNBC.